0001104659-22-080262.txt : 20220715 0001104659-22-080262.hdr.sgml : 20220715 20220715172250 ACCESSION NUMBER: 0001104659-22-080262 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220715 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220715 DATE AS OF CHANGE: 20220715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 221087628 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm2221222d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2022-07-15 2022-07-15 0001761612 us-gaap:CommonStockMember 2022-07-15 2022-07-15 0001761612 bcyc:AmericanDepositarySharesMember 2022-07-15 2022-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

July 15, 2022

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Blocks A & B, Portway Building,
Granta Park Great Abington
, Cambridge
United Kingdom

CB21 6GS
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On July 15, 2022, Bicycle Therapeutics plc the (“Company”) and certain of its subsidiaries (collectively, with the Company, the “Borrowers”) entered into the second amendment (the “Second Amendment”) to the Company’s Loan and Security Agreement with Hercules Capital, Inc. (as amended by the First Amendment to Loan and Security Agreement, dated March 10, 2021, the “Loan Agreement”).

 

Pursuant to the Second Amendment, among other amendments, (a) the Term Loan Maturity Date (as defined in the Loan Agreement) was extended to July 1, 2025, (b) the Borrowers may request additional Term Loan Advances (as defined in the Loan Agreement), subject to satisfaction of customary conditions, in an aggregate principal amount of up to $75.0 million on or before December 31, 2024, (c) the Amortization Date (as defined in the Loan Agreement) was extended to April 1, 2025, and (d) the Term Loan Interest Rate (as defined in the Loan Agreement) was decreased and capped to be for any day a per annum rate of interest equal to the lesser of (x) the greater of either (i) 8.05% and (ii) the prime rate as reported in The Wall Street Journal plus 4.55% and (y) 9.05%.

 

The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the Second Amendment, which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

 

  Item 9.01 Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit No.   Description
10.1   Second Amendment to Loan and Security Agreement, dated as of July 15, 2022, by and among Bicycle Therapeutics plc and each of its Subsidiaries, the Lenders and Hercules Capital, Inc., as Agent.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 15, 2022 Bicycle Therapeutics plc
   
  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 

 

EX-10.1 2 tm2221222d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

 

THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of July 15, 2022, is entered into by and among BICYCLE THERAPEUTICS PLC, a public limited company organized under the laws of England and Wales (“Parent”), BICYCLETX LIMITED, a private company limited by shares organized under the laws of England and Wales (“BicycleTx”), BICYCLERD LIMITED, a private company limited by shares organized under the laws of England and Wales (“BicycleRD”), BICYCLE THERAPEUTICS INC., a Delaware corporation (“Bicycle US”) and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of the Loan Agreement (hereinafter collectively referred to as “Borrowers” and each, “Borrower”), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively, referred to as the “Lenders”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for the Lenders (in such capacity, “Agent”).

 

Borrowers, Lenders and Agent are parties to that certain Loan and Security Agreement, dated as of September 30, 2020, as amended by that certain First Amendment to Loan and Security Agreement, dated as of March 10, 2021 (the “Existing Loan Agreement”; and the Existing Loan Agreement, as amended by this Amendment and as further amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”). Borrowers have requested that the Lenders agree to certain amendments to the Loan Agreement. Lenders have agreed to such request, subject to the terms and conditions hereof.

 

Accordingly, the parties hereto agree as follows:

 

SECTION 1          Definitions; Interpretation.

 

(a)           Terms Defined in Loan Agreement. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.

 

(b)           Rules of Construction. The rules of construction that appear in Section 1.3 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

 

SECTION 2          Amendments to the Loan Agreement.

 

(a)           Upon satisfaction of the conditions set forth in Section 3 hereof, the Existing Loan Agreement is hereby amended as follows:

 

(i)            Recitals. Recital A is hereby amended and restated as follows: “Borrowers have requested the Lenders make available to Borrowers a loan in an aggregate principal amount of up to Seventy-Five Million and No/100 Dollars ($75,000,000) (the “Term Loan”); and”

 

(ii)           New Definition. The following definition is added to Section 1.1 in its proper alphabetical order:

 

“Second Amendment Effective Date” means July, [12], 2022.

 

(iii)          Amended and Restated Definitions. The following definitions in Section 1.1 are hereby amended and restated as follows:

 

“Amortization Date” means April 1, 2025.

 

“Maximum Term Loan Amount” means Seventy-Five Million and No/100 Dollars ($75,000,000).

 

“Term Loan Advance” means each Tranche 1 Advance, Tranche 3 Advance, and any other Term Loan funds advanced under this Agreement.

 

 

 

 

“Term Loan Interest Rate” means for any day a per annum rate of interest equal to the lesser of (x) the greater of either (i) 8.05% and (ii) the prime rate as reported in The Wall Street Journal plus 4.55% and (y) 9.05%.

 

“Term Loan Maturity Date” means July 1, 2025; provided that if such day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day.

 

(iv)          Deleted Definition. The following definition in Section 1.1 is hereby deleted: “Tranche 2 Commitment”.

 

(v)           Section 1.2. The following line in the table in Section 1.2

 

Tranche 2 Advance 2.2(a)(iii)

 

is hereby replaced with

 

Tranche 3 Advance 2.2(a)(iv)

 

(vi)          Section 2.2(a)(iii). Section 2.2(a)(iii) is hereby deleted in its entirety and replaced with “[Reserved]”.

 

(vii)         Section 2.2(a)(iv). A new Section 2.2(a)(iv) is hereby added as follows: “Subject to the terms and conditions of this Agreement, and conditioned on approval by the Lenders’ investment committee in its sole and unfettered discretion, on or before December 31, 2024, Borrower may request additional Term Loan Advances in an aggregate principal amount up to Forty-Five Million and 00/100 Dollars ($45,000,000), in minimum increments of $10,000,000 (each, a “Tranche 3 Advance”). The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount.”

 

(viii)        Section 2.5. The phrase “after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, 1.50%” in Section 2.5 is hereby replaced with the phrase “after the first anniversary of the Closing Date but on or prior to December 31, 2023, 1.50%”.

 

(ix)           Section 2.9. Section 2.9 is hereby amended and restated as follows:

 

2.9 Treatment of Prepayment Charge and End of Term Charge. Each Loan Party agrees that any Prepayment Charge and any End of Term Charge payable prior to the Term Loan Maturity Date shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and each Loan Party agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date and the Second Amendment Effective Date. The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means. Each Loan Party expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration. Each Loan Party agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an arm’s length transaction between sophisticated business people, ably represented by counsel; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment is made; (c) there has been a course of conduct between the Lenders and each Loan Party giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not interest) in the event of prepayment or acceleration; (d) each Loan Party shall be estopped from claiming differently than as agreed to in this paragraph. Each Loan Party expressly acknowledges that their agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders as herein described was on the Closing Date and the Second Amendment Effective Date and continues to be a material inducement to the Lenders to provide the Term Loans.

 

2

 

 

(x)           Schedule 1.1. Schedule 1.1 is hereby replaced with Schedule 1.1 attached hereto.

 

(b)           References Within Existing Loan Agreement. Each reference in the Existing Loan Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Existing Loan Agreement as amended by this Amendment.

 

SECTION 3          Conditions of Effectiveness. The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:

 

(a)           Borrowers shall have paid (i) all invoiced costs and expenses then due in accordance with Section 5(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the date hereof under the Loan Agreement.

 

(b)           Agent shall have received:

 

(i)            this Amendment, executed by Agent, Lenders and Borrowers;

 

(ii)           certified copy of resolutions of each Borrower’s Board of Directors evidencing approval of this Amendment and other transactions evidenced hereby; and

 

(iii)          such other documents as Agent may reasonably request.

 

(c)           On the date hereof, after giving effect to the amendment of the Existing Loan Agreement contemplated hereby, there exist no Events of Default or events that with the passage of time would result in an Event of Default.

 

SECTION 4          Representations and Warranties. To induce Agent and Lenders to enter into this Amendment, each Borrower hereby confirms, as of the date hereof, that (a) the representations and warranties made by it in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof provided, further, that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; (b) there has not been and there does not exist a Material Adverse Effect; (c) the information included in the Perfection Certificate delivered to Agent on the Closing Date remains true and correct; (d) Agent has and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrowers to Agent, pursuant to the Loan Documents or otherwise granted to or held by Agent; (e) the agreements and obligations of Borrowers contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrowers, enforceable against Borrowers in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors’ rights or by the application of general principles of equity; (f) the execution, delivery and performance of this Amendment by Borrowers will not violate any law, rule, regulation, order, contractual obligation or organizational document of Borrowers and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues; and (g) no Event of Default has occurred and is continuing.

 

SECTION 5          Miscellaneous.

 

(a)           Loan Documents Otherwise Not Affected; Reaffirmation; No Novation.

 

(i)            Except as expressly amended pursuant hereto or referenced herein, the Existing Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. Lenders’ and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.

 

3

 

 

(ii)           Each of the Borrowers hereby expressly (1) reaffirms, ratifies and confirms its Secured Obligations under the Existing Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3.1 of the Existing Loan Agreement, (3) reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Existing Loan Agreement, including without limitation any Term Loans funded on or after the date hereof, as of the date hereof, and with effect from (and including) the date hereof, such grant of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Secured Obligations under the Existing Loan Agreement, as amended by this Amendment, and the other Loan Documents, and (4) agrees that the Existing Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.

 

(iii)          This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrowers’ Secured Obligations under or in connection with the Existing Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent’s security interest in, (on behalf of itself and Lenders) security titles to or other liens on any Collateral for the Secured Obligations.

 

(b)           Conditions. For purposes of determining compliance with the conditions specified in Section 3, Lenders that have signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to Lenders unless Agent shall have received notice from Lenders prior to the date hereof specifying its objection thereto.

 

(c)           Release. In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and Lenders, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or the transactions thereunder or related thereto. Each Borrower waives the provisions of California Civil Code section 1542, which states:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

 

Each Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Each Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above. The provisions of this section shall survive payment in full of the Secured Obligations, full performance of all the terms of this Amendment and the other Loan Documents.

 

4

 

 

(d)           No Reliance. Borrowers hereby acknowledge and confirm to Agent and Lenders that each such Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.

 

(e)           Costs and Expenses. Borrowers agree to pay to Agent on the date hereof the out-of-pocket costs and expenses of Agent and Lenders party hereto, and the fees and disbursements of counsel to Agent and Lenders party hereto in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the date hereof.

 

(f)            Binding Effect. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

 

(g)           Governing Law. This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

(h)           Complete Agreement; Amendments. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

 

(i)            Severability of Provisions. Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

 

(j)            Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

 

(k)           Loan Documents. This Amendment and the documents related thereto shall constitute Loan Documents.

 

(l)            Electronic Execution of Certain Other Documents. The words “execution,” “execute”, “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

[remainder of page intentionally left blank]

 

5

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.

 

  BORROWERS:

 

  BICYCLE THERAPEUTICS PLC

 

  Signature: /s/ Kevin Lee
     
  Print Name: Kevin Lee
     
  Title: Director

 

  BICYCLETX LIMITED

 

  Signature: /s/ Kevin Lee
     
  Print Name: Kevin Lee
     
  Title: Director

 

  BICYCLERD LIMITED

 

  Signature: /s/ Kevin Lee
     
  Print Name: Kevin Lee
     
  Title: Director

 

  BICYCLE THERAPEUTICS INC.

 

  Signature: /s/ Lee Kalowski
     
  Print Name: Lee Kalowski
     
  Title: President

 

[SIGNATURES CONTINUE ON THE NEXT PAGE]

 

[Signature Page to Second Amendment to Loan and Security Agreement]

 

 

 

  AGENT:
   
  HERCULES CAPITAL, INC.

 

  Signature: /s/ Jennifer Choe
     
  Print Name: Jennifer Choe
     
  Title: Associate General Counsel

 

  LENDERS:
   
  HERCULES CAPITAL, INC.

 

  Signature: /s/ Jennifer Choe
     
  Print Name: Jennifer Choe
     
  Title: Associate General Counsel

 

  HERCULES FUNDING IV LLC

 

  Signature: /s/ Jennifer Choe
     
  Print Name: Jennifer Choe
     
  Title: Associate General Counsel

 

  HERCULES PRIVATE CREDIT FUND I L.P.

 

By:Hercules Private Global Venture Growth Fund GP I LLC, its general partner

 

By:Hercules Adviser LLC, its sole member

 

  Signature: /s/ Seth Meyer
     
  Print Name: Seth Meyer
     
  Title: Authorized Signatory

 

[Signature Page to Second Amendment to Loan and Security Agreement]

 

 

 

SCHEDULE 1.1

 

COMMITMENTS

 

LENDERS  Tranche 1A
Commitment
   Tranche 1B
Commitment
   Tranche 3
Commitment*
   TERM
COMMITMENT*
   HMRC Treaty
Passport scheme
reference number
and jurisdiction of tax
residence (if
applicable)1
Hercules Capital, Inc.  $15,000,000   $0   $45,000,000*  $60,000,000* 

[***]

 
United States

Hercules Funding IV LLC  $0   $9,000,000   $0   $9,000,000  

[***]

 
United States

Hercules Private Credit Fund I L.P.  $0   $6,000,000   $0   $6,000,000    
TOTAL COMMITMENTS  $15,000,000   $15,000,000   $45,000,000*  $75,000,000*   

 

*Funding of Tranche 3 is subject to approval by Lenders’ investment committee in its sole discretion

 

 

1 Each of these must be included if the Lenders who are party to this Agreement at the date of this Agreement hold a passport under the HMRC DT Treaty Passport scheme and wishes that scheme to apply to the Agreement.

 

 

EX-101.SCH 3 bcyc-20220715.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20220715_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.PRE 5 bcyc-20220715_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.LAB 6 bcyc-20220715_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jul. 15, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 15, 2022
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Blocks A & B, Portway Building
Entity Address, Address Line Two Granta Park Great Abington
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB21 6GS
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
XML 8 tm2221222d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2022-07-15 2022-07-15 0001761612 us-gaap:CommonStockMember 2022-07-15 2022-07-15 0001761612 bcyc:AmericanDepositarySharesMember 2022-07-15 2022-07-15 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2022-07-15 Bicycle Therapeutics plc X0 001-38916 Blocks A & B, Portway Building Granta Park Great Abington Cambridge GB CB21 6GS +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2221222d1_8k.htm bcyc-20220715.xsd bcyc-20220715_def.xml bcyc-20220715_lab.xml bcyc-20220715_pre.xml tm2221222d1_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2221222d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20220715_def.xml" ] }, "inline": { "local": [ "tm2221222d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20220715_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20220715_pre.xml" ] }, "schema": { "local": [ "bcyc-20220715.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20220715", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221222d1_8k.htm", "contextRef": "From2022-07-15to2022-07-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2221222d1_8k.htm", "contextRef": "From2022-07-15to2022-07-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20220715", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-080262-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-080262-xbrl.zip M4$L#!!0 ( -B*[U2L0!!#R@, !H. 1 8F-Y8RTR,#(R,#@UD2?:Z:52[139! J/.IHB;7O)24!1M$Y%(E:1B MNU^_0^IBQU9\:ZLG7LXYG*%FAM-[-T\3]$2E8H+WG:#E.XAR(F+&)WWG?N2> MCRX& P>]>_O7GPB^WM^NBZX83>(070KB#OA8O$'_X92&Z)IR*K$6\@WZA)/< MK(@KEE")+D2:)513V"A."E&W%70BY+I[Z'ZB/!;R_FY0ZTZUSE3H>;/9K,7% M$YX)^:A:1*3["8XTUKFJU?RY7W[[T6^8(C7Y!)]W9Z?S._9E0OGK?(@[#^0S M_OS^(KJ-?SS3T]-KGY#SXLB>(E.: M8@0_@ZN^8_PKW9MU6D).O+;O!]Z7F^'(XIP"&,X3QA^;X,'9V9EG=ROH!G(> MR:22[GAF.\**ULJPR[;@&5<:<_(,'^N:L KN>L7F,RAKA+XJH*R"QG0-IRAI M3<23!QN ;P??_ZF@N7(G&&, M,WMNF:(! M."ZD1GRC)FU[:XI7^;]OLI%:OX(::5^HG@:.[$ MCC5D1VB4'9?M6TS%_G:>4LD(YI&ULU9U;<]LV%L??=Z;? M@:L^R[HX;C=NO!U'MCN:)K'78%AZ)2&U[D MP9&IP%F(8\(6Y[U?IOUSV>3Z;07 M2(58A"AG^*S'>._G?W_WCT#_^_#/?C^X(IA&I\$%#_M3MN _!5]0C$^#7S## M BDN?@J^(IJ8(_R*4"R""8_7%"NLO\@*/@U.CD;'\Z#?[W#>KYA%7/QV.]V= M=Z746IX.!D]/3T>,/Z(G+A[D4<*:02N3O;<#/,_V7N'RAA#Z?FQQQ) M'.AX,7FZD>2L9\K-BWTZ/N)B.1@/AZ/!?S]_FH4K'*,^829N(>X57N8L-K_1 M^_?O!^FWA6G#%#(V9U9?QNIG4/9^&20?5DV)2VG+HF6Y%2F-?G$ M0Z32%K)740!:F-_ZA5G?'.J/QOWCT=%&1KV"4QILP2F^Q8O _*]![TJ=DW ; MZI:ST@UKC1-%PA3SP-@-)EPW8RTZ/<-*X,59;Z[-=4'C\?#'T8DIYON*D=JN M=7.6Q+3&7C"H2$ B+%38C,NE !4NXFYJFA6^TJ<083+'_8C$F)F6WPOR@LK5 MW)V%,#70IH/<9F ]P>OKWA76CWB,R(&BF]X.%*% M(#E/N26ROT1HG8H?8*ID<22M0W\XRL>/[_/#]V8PQT;:'9H_-ZZ2^MRP M;E?7_,S_7!3J\\;3\0K-6NQIR)G2+>:2IJ7I5H^7YD.A;"%XW#&L>0AY:SW* M<=9R>@$7$19Z9C=\5D2YQ-%93XG$4O$W@36A2,KKQ4SQ\.%\0VRMKE[?ILN+ M(K0.M75D[0P 4%!=+EDY9Z$4^=$-8;+8ORJ,YB]@' XPSWZL< C(>^DSD M?F21_U)0BE'TT%[OQ:BEM8/ ';\U.!['G*5J/^<32Y!;W?05L%6GN "2E@N# M=U ,=FK?VJLUDSESY/X\QH*$B%W@-9=$(;&=K9# $HRS\6IWNK==Y_\7$>^H M'>R_7F1$.6Q2>:?/VCZ)-!;W[QR'_,#9EDTN%.47Z6NZ!5FW!18945<4+>U1 MKIAX$.:FWE>='AT8YPLL0T'6JC0=!,)=LO0IZG798%?BOB>YQ4LBE4CKLILO MM'9RG3!4+?VB(-5.@3B!_<@9BM,J7F^B%BG*Z)I M[Q$,0#R$X\>WQ7'Y:*87>@SK3F3GXBF4JGZ(R[_<<[G1*22/](Q"="!2,_:( MA4TY1.']6U&X9%%7!KFI=P3*NML>4+@&<$5DB&BF\4H?V_.TJV'N$0B[]A>_ M2?>W8?R!D>B,8F?L'8BJPM5G=RH/(6R6#$7>83&?"BILM3)EU@6U1KUIZ$WF+;##Z#I/H3-Q$ MUT8@.F41WOR*MVWAKYEZ$W^;;A" P^0Y4W)I%P?[=3M_4&@54XR,!A MQIS)NT.;::3K1!8D6W"['P7@X@V1-OT@&(L) &/?0-24@QB< MI]FYOG1,NQ8W@C^2;._3/A8U#]^ V.2#5)RGXD6KR2897:Z,S-(W"F798/2= MI^*YN!LN%:+_(^M]M/(BV53(8<9U!S&N:H6"^S([/;H%]W=!E-9D]C\D++][!3RWM)IZ$'18-PC 85H[XY2$ M.E9L^5G/9@5!U![]IIT'H0=$@W%WF,'>"&Q:!-:)0[HHT&R'%M>+!=2CP_8> M<-@C'N3A,)6M29Q*F6!Q*)6&EW]L[%4 "3E,:V8S3;QG-.X0U2%D,/X@ZI!D/O,&NM*+,'O6+B0;B; M>L% .\Q:BXOO-V*S=*#L(.RP>@[S&:?N[YEISY]Z5^?ONS0ISO, M9@MAV68'?3U>SRE9(G@W9HN#1QP@]1 26\U>"TFV-ZY4H2O]P0[#:NH!!E@W M",#EUN0D(@I'F<@KPA +=:JXVRP*W(_8Y^4#EBY5 DY?][[.Z;T5\:?V PC MR1F.LF2E[;D*X.(!F_WZ03#.GP!_Y31AYC4:ZO%:NH-")MN$(#SA[WY M@OS=*)>]C[6-@]W#&QPM\D$JSA\"3YG" H6*/.(+I%"NN8V*W<,;*BWR02K. M%VFG%_!$#W%+WKXNHF+H#8.F:C#TSM=FSV)$Z<=$ZDK(UMZI8NA-Z)NJP= [ M7WU]&6.QU!WE+X(_J56^N;H-@=7!&Q2P>A")\U76EYOG5T%DNTI;>32L_8%A MEPZ1.'F#;O'Y/-&21Q]W-[B!19F<*;W_,*A54Q?_H+_+CYL?YB\*Z2-_ 5!+ P04 " #8 MBN]4<0MV 0\, VD@ %0 &)C>6,M,C R,C W,35?;&%B+GAM;,V=77/; MN!6&[SO3_X!J;]J9R++L;COQ)KOC./:.9QW;C91LVTPG Y&0S#$%>$'*EOY] M\4%2)(A#TMXL@%PD"OD>\ 7Q" IXO#-3]MUBAX)SQ)&WXZF!X/V0GD\G3T],!98_XB?'[["!BZV$%SG*<;[*JM,/M M8?%'A[])$WI_(O]:X(P@<;YH=K+-DK=SBL$_'!XRO)D>'A]/)OS]'HV/IP?;+!Z5)U^=0Q/-!K>:#I/^2!OBLV7^$%24=(*@4? M8+U>-\HJ@B:NS=X2GK#XG+[,M1GMR;[X[O#\=U2@'N^\"G.6X_1%YNN1SFU? MDY>=\7V<^S,M^GGRLC-=B_Q#;.=MR\\^O?;SFLJ-5^)3PR+9YF( (W%I4A;1 MT0.K(ZB!H2B[*IU%C7)3V9LSWJZ['!E5F4N<+53!FVR\POA!'.!H.B%IGI5; MQG++^'!:]-_?%9N_RA&2K G-SU*<93?+6PA'Z?ZU.OP)6?K03:*,\<&B+^FBZI\?:J%!: B#1DG M&=OPB#RKI>NU&7I6"X?K5$3(:1NAXT^ST8]*AM@2*2'Z(J7_>S/9%^V1*#$% M7#.JC'T@ZP7A0)TM.I<$@3;KY+1$P1 #.6N1HG0E)UKZNTE91+M(-O_1X3^G MWZO&EUN^GJ[%P!]A^IX\L"P1P_]N=H=%Q:T8#(IP <0SK$LT!LB]0S++_;P ZE<+D9*GQT,AB:*.Q-'"1XI6E"L9^5\ULM56V M9!%/'F0?TU67ALQYPUM,MMJ_I@D+@[8QF(::UF,G_Y&LDBSG:N"I9C$=71J@ M=ST,=-HVQP6K. APAC@$1XYZ$*JB/+)T2ND&IQ_%M1+O0J@I6HNTV",5_]I@GA.>[GK!:"E=LP%8-?$P9$$18O<&0E+)_7,RYYAF MB>S,>D%I2YU?A@!F6Y2I,*0 MC/-(4^WQCAZ.6DK7! %6378,65#4V+V!O&@Y4OHP0#FG\2!,*IT?2 R;=D0* M48" -)WUX2'4ON&X2+((I]K/A=C6]8N-1>L:$M"N"4I+&!0LD#L0&!U0NM#1>J]@7*VX;SA'!Y]8*DK5/K,EJQ MNB!@Z3'7>AY)RQNP>!R-SFF>Y#NY=N%Z8WE(R2YQQ0=DKN3"W!\$#X IDP,M M0U*'M-!;ZY>_*M!<+AH!JV3*W%)@-]DDH:D)B :K,8"(O5:MX?%&Q9GHI3A. M+VE,MK^0'5BWELXM%X#-)AB&*" R[,X - HQ4FHDY-[@N.7)6CY0F40]PT9; MZ!8/R&B3#U,5$"" -8"00HUFEV>^1Y4YWE[& MADF>BU>#VD@'JWP/38;G(# MB /"I]LA0)$(0LTHWS!=THCQ!U9[7.*,;41GN#MC,3QCZ8ER"]:@*C3QZ@P) M"+(A/@'4&J&O]#,MB,EUU*H )$OP1MUI'(N3E17_7"643,%S8-6Z):S#;I,K MBS @FF!W $.%\E7Y "LYQT. ^YPS\?&&S]F3[8%O4.D%F[95*S1[67C(M+SU M 2,#Y/Q&AOA&14VV;O@M9X\)C>!I-"3W @U@VDJ.H0T/'[O!/H:J27(9YQND M8K+>^V4I97YZFZ9)>U>C->&!TC36V\EHM6\L;EF6X_2_R4/G1;I=[ 41JV$K M* UE>+C8[/5!HV.0"/)UT5U@*W\ L2Y7,_8[^Y7:9JOZ:;J^,P@0;([:23'T MW14M\M'4DE5.,- S-'<[:VB+J:J=:_O":.:VH58KJ^^WT/CZ0LLL?.GM':/P MPP5MB:O6ALR5+6[N#Z+5 5-FRRL94CJ/=^YE-K#,WI77]CD;Z4T[U[@BB MA4TWK6&[W.^A17_E22Z.+E,J;6CQRY#M&41 YZJE.VV6K6X5!4% ES.3AD*+ MFF(/:,Q8FD1)GM#5!W%QRA-LJYE-Y H*V&!)1%L1! Z@K59&HDJ(2J4'$&XY MD3 2T1AJP:%,",EOEDOKZ-\E=@5&O^$2$%@9!"B]]DQ@1, XJD4@'8)4C']T M+K-L0_BS +*$>,((- _ U-*'B!1DLAB;KQF)-F*\W$V/%O,D;^7,LTN< MC4^ N6IT,O8'P0=@RN1![9/96J='?UW\#951'A"X9G..Y0L 9KOU@J5 )BRK MRA4('19+%BR2('" ?9E$7#-42)'6^LJ4U3!LJ9*QWQ4$5EME\S=V!M'P-D>M M3J#1WAZ[__-M=">,$6"Q@UWF>ABPF32'@KHF" PZC+4N5@HI*K6^%COLA[!5 M_Z1@Y6U2L.J9%*Q"G!2LADX*5EXG!>6A=9H2T4?=+-)DA8&DB9UJUV!T6#89 ML4B#P@7V!_8=50C:Q_C(MJG2KM72^5Z(#Y:: CIG^3:[;%8)-VVB(#CIYY?X@S8@::K^#IT8?!T3"3 M+:1T6)ECL0KJFQW;S MP1M ' 120QP"C]_(H/&]C$)E6'&WS!M-GUFZH?+%%^J-AK8>"M"YI0>PV:3& M$ 5$B]T90$DE1EKM;U&XSEY13;ST^R7!2D)RQTO$.TT;*\6MVH"XZ30(K1LO MK!:;/#0D ?%@\P7PH*2HU'KCX7Q-^$H,=S]S]I3?%3ED MP?H!:K=\=%INO(*YGKM?E^'Q+2A3)!1=ZMDYC MS&T8=8F=OS$%--QZ;TI+&01,O?;@=ZA4$:@,\4#.C6"9UZ_QE!'Y?D!P)45_ MB"N*AIHO6>K3!T'40),F5RJL>>&M M6['GUG5:HGY(>G?0V1X]FRQ: Q6:XI M@N $M 5-E>OO-_"7SV^S2)/H(F48O@O3T#C.XM>V9R3PVPL"HJ#M"DK;IX1( M*;TQ\ [3>[YYR*/=+6<1(?)IK:SJN?KNT0V,=LO-LZK4)&I0:$"L/<;@.^:=08Y_BAA0 >,'B8Z( M@/ ;8!/Z<4)%(A7Z"NE@5(OV>-V6[;,3DOC=[B-9$B[7-,S)-G\G#G;?<>4Q M(-;U5=W@ZI@7>;V!08#X7+?0)6"&Z@6@A7S.K"@"?9&%(%5*YWO:_X"67$2[ M2+YVF"<1IN]%EYPE\A=A_87Y0,P+JP'RKS&+G+5:7)Q=VV.5P[U:WJVL@M ^ MJNA"+*U3WW0E/HG-Y2;QUP)G1&SY/U!+ P04 " #8BN]4\*E,VDH( !F M90 %0 &)C>6,M,C R,C W,35?<')E+GAM;-5=75/;.!1]WYG]#][T.>2# M=KM0V X$Z&1*"TMHN[LOC&(KB099RDHR)/]^)=L)26S)EY8=:?M @W-DW7.. M+.G:DCEZOTAI]("%))P=MWI[W5:$6?]BEG"Q9>;X?J\,Z7F\K#3>7Q\ MW&/\ 3UR<2_W8I["3CA22&5R?;;NHEO^*XH?4<+N#\V/,9(XTGHQ>;B0Y+AE MZBVK?=S?XV+:Z7>[O)<\1BJWO;&:R(HPO[57L+8YU.[UV_N] MO85,6BOQN8Q,M8-X>9;BUSG"D2Y]YU#*XSX+IMZJ#S M,\P$GARWQAJN*^KWNV][;TPUK[9 :CG7;502T\1:46Y96=C*42*%:KLU$TQC2OXTYC M=B"='XYL@N0X;QR9;$\1FN?A=3!5,9H>NV,1$\M8E85LB= M47.18*'[VV[W)52'M8=5.S1]GTA7%P$>ZL!D??-PE_"LO$79;?D;291&]%_& MB!=H_@.*I+R:C!2/[T\6I,Z97>;5(O\':YI9K"\2O]9L!G;&4T28W9,Z;&!F MV!K8CB]U3$I#?/O!TY2S/+!/.!T_#;TU=E2A36ZL.X3_R =[:]HUP$9SHZ5\ MEPW5"90Y28D%BQ,[PG$NBD%B.9IJ0M&IL2C45 JJ][T]M"(N7T?T'ANQ; M?5;W$%T@@'*_N-J-PZQU5-YDYD%@[3Q+3!P7%$WK%=Z! "7N!:!Q+3F?(I]A M&0LR-W$W:+V%]-9E_X#D-50]]A\W>$I,?F+"64\$W!V*I8BW#OW[NQ@G>8^F MG#"6(7JCQQS1X,4V$FC!ZX LJ*/J4?D_,B04%G0)$;\"!NK_)B#]+81]SF@$ M8GJJI>.'>%!% TWX-2 3;)0]NC":84K-[7C$0-="'1[HQ-N G+#3#L2+\P8^F7.O$D"=ZUB =E3 0",. C+"0MB[!>#TWV'K4?T+(F-$BZ@N]+&&)P4U<*@+(63,C:R]._$71@+LPP88ZD(( M270#8P\>##(AM@)R=D=V--2%$-+G)LX>;#AGBJBE643R.;/P@I MLXVC-[E7MT^8,LME7)+O(J&RAY IN[AZDWZ@XQ>(#EF"%Q_QTJ5]!0H5/X0, MV/6ZU%;"-HX].W&S?D]8^8^-K\!+& 2NL/*@[#=!E(["[$?(6'DORO+XT0*%*AY" M\NIDZT']$:T\/8A^+;!I %BG!/G*/;,Q M6%Q-)K9>W(6'FA!"IMK,V[\90RDS+)YK24TIJ#$A)*U0#7QT4#C.=)^Y[/7' MMV;ONZ5[JJ"@\H>0L-HX>I#[,[\5R+R>8[1,QYS:]RW5 J&BAY">.IAZT'TK MEGK%=R!0K4/(2VO9>>Q,SA?Q#+$IMB\YJ4="-0\A3W5Q]=J/3T']^/29_7@( M^:J-HT>YB_T'^MJ[&E,R1?:]DK>FY79#RXF6"+A-L):!>A) /0[A[7*"HL'D5&WG 9TBA,DJ7);824$M" MR)8AW+UNV1 #/9!-N7M5PPX0:D (*;2#J3?=1RFB]#23.FSI[)1V@%#=0TBC M'4R]Z7Z>8C'5/>('P1_5K-S7[-+?4@#J0PBY-8"Y/S\63R]?*'9U.LVH08-? M^A&.$U;./M]Y$\=F!4PQ66 )$A8C7'BH%2'DV%#]%[%YD3ZN@3D;L 30%T*)[M^EC+^[G\\O:6V M>&?J5:;R/Q:A8W3>!7&6@[H53N(-T<'CO$L^[57$R>GR!D^P,(M);O%"G>K* M[MW3,$!QJ&4AI.K/5J7&N:-.A::N\EY_6WYC?I@_BJ&/_ M02P,$% @ MV(KO5-VBIPBK%@ N'@ !( !T;3(R,C$R,C)D,5\X:RYH=&WM/?M3XDJS MOUOE_S"7<_>4?BN/\%!$EZ\04%$7%'!UMTZ5-20#1$.2S4-@__K;/9- @$11 MP=T]=_<)829A6+VDM+^_GQQAG9BH5!B%UDNG M4E+R]O-%2^ZS 8VKNNU076:31IJJ/T3#Q]))U8ZEJ3-5\8V/))-< VERK1! ML/)N4A3.5'5"J^9$5<>OJMI&-BWM/46'J#%I,(JJ*R'-P"&[/6I>3*L[X?6G M59..176[:U@#ZD ?(J144 MBSO4GDA<87/B]G%" ;1(2]^S?E6+=2,![R:AU*_HVO$>I>:D)8<6=L,CN<+"A.8C&V3&'+]*2E;+BZ8XW#.?<* M.4*_@6TYBZ3!RQ"J.O)XVHL=%9XTYO2914WF.JIL)V1C@,W2J3TI%^.CEE$% M_A+\=^BHCL:*ATGQ%TH'S*$$P<79=U=]_!0K&[K#="?>!MYB1!9/GV(.&SE) M,;B3V"[I@3W\GWB<'*M,4PJDQ9P#4J<#5B C971 :A7^X2Z5+MU=MSZD*R>E MTB7\0:Y(/+YLZTSY#KF^B^#VSN?V!2"S^4FKUS3/27<,-!A8@?^K.@AS7 8I M652KZ0H;G;/Q70JLW-ZNM"NE7P)W/P"W-&"Z C_.L49[=UVJV>P%H/;2=ZW& M75N ^J?"3.=8!3V'!Q5'.LG#IW-2-M#LDS8;F!IUF/W/QX\?H:#9:&#+JL80 M/WR"U_]4#-G%QYH^,1 78#=J#AO8"91D$FO'H)#."P M3RUFWZ7O^$P@@-C\W4O@5)"62P]69H&D2. =0QD3VQEK[%.L"^.D0*24Z9"V M.H J=38D36- ]1WQ8@<(L-0N'Y&*^NBW4U0;)#\N$-W0&2]41P4<6LS",CCM(I= M"#R&R*)-1S40KZ-V59GK-.#H, ME$D^)?V\B:/KISIN?[LK&8&#H+<>0'SXS MCBQ,5H[EL@4.TOD@!W6C;5'TTEKC0'K,%C5P M]B[8W"T#3@CWM0I]/C&C 8[[EC(QLI685XQ3X*>8K8(!86)J\%#- A?H;,.U M?&Q0C0^L@B<[SNH3G>E/87XSQKMO\G;R7O5ZDUF$L\)"?9YR[7Q6[><;3]$E M0_%YV$R0KZ$L4@&.I^54P*06IRSXD*9E"\U@-$0T\DOFR9HAP'_IB719.2^E MHS]+_E.1LAY:BD"!5Z0 ,2-34V75$;02!2RN+J(9CZ%"RP'I8?NR1FV[T>6L ME4:J'2OZ519X/DR&@@^2E@RG[?^7TLBN[8 ?5N+&ANK@;!BV"O2.Q9SZKU<@ M-(Z%I[G_HTH%5U>%'H%/M: , T9MUV)%S_DJ0!T?F%\TBP*A1< 7D[RP-J]52]0,#+CD$,:_(* M01^_Z6HL?DE[/% *NMFB9=PQ3'#2TR9$ MZ;CN& Z2J0#+X;JHK31R\^]2$V MT[QC6$"7:'ZD4?F! QB&YJJ'!"OT(TFSH0 M''J_ RPD9WB8Y7_9(,/GCDN*I X(#L8XU=0>O)+!D* UGLAO/>!]+B.02*OA MH5.\KM?:U0IIM4OM:NNP8W$7M%4M7S=K[5JU14KU"JG>ED]+]9,J*3<^?ZZU M6K5&W:]Y0^T^.-". >@KB7*"I%.Y[/YALO.3Y9-=E7R.&\W/Y- VJ>['$G?[ MJ2.>9HC'_9 >5_&WMQGD <&\-/X/X8L5\_'P^4#E, M(J7%GR__%8TQ+O< 9-\.9+D%ZQ1!39O5>ILTJY>-9MM72L&^D$0G&D@&@5RZ MENU"M$@< PB3,8*%$F)81,IM*=O$Z!*GS[#(M51'!8:J([E/=; O)=G!8FD_ MDWT_N0-#ONB?P)5>K_A3GOCGQT5N;EQ<F*ER?\ &2<4;[]O#RQ^XC??4 M"4;_"GJ9T*ZOT/&8P5RLAPV@&<)BQ3-7&T-_[Q"$^N28\CZNM8N1)E2L)GC" MED.V_&?@1@,%= A[A)K$XL5,V5X9.>]G5><5)^\ICL@I-5E/M7$IQ<%\8[C> MW#STK#/Y^UC^N@*[&H8V5CP2^7+2#B3,B:G)/\_H;E5'%(P.$HX*84T()M0F MMLEDC-P4HH)H'9N F0+]L-:H'P[M@'QDIFD@ 9DO=Z9B_-FDBN(_OQAIP(^< MN(>RH6G4M,'Z^)]$X'#H6#Z"1V9!%U'-EQJXFWYP<>@H?BT/>";]8=:U3*$' MNQ(K6)I1YIHN&Q:,5)XQK5%8(_-U3#*.=Y2^DHD5V0_C!5J">JK;&GCF9Z M"A=X1/8ZO%N&6N]R;'W1,O65F9PI2DS&2/%,?E_:_>W%.CL (E8([I311;B< M+_9:5']\')V=R#'"%UH_Q0J%V\IMH3!=5)@C"W4\KH[B(D'/5Z8"JQ;%N@$F MTL3,$5JLB11#Y0J_K)>9%O_3FHP^'XGHD1JX=$ONP1&U%96[JL(2KQ$YS#)J MT"KPR616KT*5;E(27)/H+@ZQT?5$2^T5_5?U.M8-*PA1F("-8= /?+BEMKK U&Y1!9- MKO]68]WIRQ<8YJG=3<_8W9*B6,RVO3^XU4 *M[=VO9L[.[N^NAYKPIRO9FX+ MP0\^M6;(#[8078G\30<@HJ,=<@F1S)".R9&K:BB,Q2DP&-'OB$!_(2TC/<-_ M.IS_W&V_GQ]=LDI=7=G$'H(\5CQ!5YT*YB^I]4!.+$8=4NJ(#-I3\SXPO5,^*(1:81ZK9]>PX]JAB# M)Y@/R\R+!'EJ(;F>$MGF<'=NWNH,P /2V)H-SZ+/EPGKLDO#=JCV336C8QV[ M5?HZM.[KH_WTJO5Q!CNHY%%:$M+;/6D]Z6._R@GT:ZU:UEL>-QCPFQ8X8ZI) M-<)&3'8=]1'S # Y,WL[7#M63@V(DZ \MW^F!_#V1,8TU_/W7_FTM'=@ U:- MF7U#9T3GWMX.>KZ:BX(B% PUJ*,"L@G1_;*G^V@ 2U S6MOW3Z6KJT'^NII; MA?4-XHL5/V:S$5J]8%_W/((O#%#G2^3YJ;AWU,Q*MS>CQI?\[@J(GL<9*TKI M=&9S([TKY5*9]\BMS:O3:X$NCH^)Y1:&/&2=E(?,6\@@(QJU_7QO8CM(]GLD?=\61Z") =O;9_(#7TB!*-PRP(YA M2-LQ1J3#-&.('&,ARH7DX^>DJVHX[%0;QJ##P!+ O.H8((V!JSE49X9K:V-B M0TQB=\>\J=?"Z !:$:IX*S>!)*D+@$#,^M@OZX)3;PRQ'6;&5(PG[<)[I$N# M@CT;Y',E5L]:>RM968K:@QM*DNC[_$&D M/9O](^1:]$ !>4%8Q RL4>+V!I)-YSQEGEN;Q"7)+6F/E(^;))U)):!B8**> M3M)OT>YG=.N/SJ]*Y_THJ&7P'6]0Z3-833"=6D1^NGES\W!R<[I[KZU5X1?I M>9VV3^% APE BZHN96E<2@>T?6;Y?:+KV51"U/RC[K^KNOLF_M)B:$MQZSO? MZX+3O]7H=J/I/\"+RP& SUI]*:O$TUN=[>4& M@ZC[9SC\KL,A%3X<:K;M,NO90:'4CG.GACX:UEZ?TWS%H%B@[KV&1H;%LUOR M* 126EWD$T'; M+[F.\[+LGH 7LDO9PYK-/)MNG2B%JD=DXL(2"S,YL10W/IUB&Q?'Q=8PN4]D M/%@QR6!&D![V\(4Z$_D_7U[ONYM M >,=SWQ3!Z-ZV%?AS73HKR"C_4;Y>.6"SX72Y20F$M+/B@P+0@46L4_5,Y9C M*=WA0RET+O7/]$'UJ"-,@3H+A^#N?G1.+F]*)ZYD#E^2/UWNX&L@*IOC)59L M6" M:HV).).R0\1I$XT\4LUE!*UQYB"52$G$Q+-B6"ERFGYB4+U6+WY*S_MK MIB%'?R,W)+U9 8[UZG77M88_OG7F-S3Q4\I+;V5*0X2C)VF(U_1;=DZ[S^;[ MISHW,GTO+G(C\)L[IUW/*YK,VO6F%"NN\5RZV(4)["RN)XF$,N+LK_^6/DH])G*S/RXIQN//[T454(ODK*\+*:8M^O]U]G M\)<[$/RD\??;DFECTO+F >XT6,R$!]S+/[-%0(5FYHKUZX^> MO4V=2\[CE]-W4I\9_F+%H_+7\K^N;T,FF_VU3#;+]G*YR2X:NC.N/=R_)9][!V(MTZ^M\J--)AYM@DEK'K)TYI3 ML)@.G#8, $ZL5>C/9W;K^1A/.,*RP!>>5W[(.&;Y M8L\UTJLYKAF55WZ"L&53RO_:4=E]8ICAIK6Y0;NYP4>MNK =I@]#DFE@&&%( MZ@;/#;LVX[4 ,=]U0_B%EBK/%XN;2KB5163:&+%SUY$)69 0=WB\X+Z.Y[RYP'T>O\I]'=$2?,\N0LX. ,IW%Q>S )E@DSO0 MBQ*/=)&?O8!EEQ,0?M7+5$/]>V$6T%N,/L0[# 8WT&ARFH,H=R-TZ*4H@QW_ M+GW^EO7HF86D%2\&KG8]6O)6!? N42)!C#[-^N-/IUC%(PJXE](@E/B[=L#5 M!3.M\EWDI9[%>#R3F%TP6,W*Z+JVFL:*#9W,7-ZP0Z).[?/)9 MW>Z=3!V7? MIX(GZ6![

I_>L[R5:@?8L7;FY,+O>

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end